SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stéphane Laurent, Achieving Goal Blood Pressure, High Blood Pressure & Cardiovascular Prevention, 2015,

    CrossRef

  2. You have free access to this content2
    Ying-Chang Tung, Yu-Sheng Lin, Lung-Sheng Wu, Chee-Jen Chang, Pao-Hsien Chu, Clinical Outcomes and Healthcare Costs in Hypertensive Patients Treated With a Fixed-Dose Combination of Amlodipine/Valsartan, The Journal of Clinical Hypertension, 2015, 17, 1
  3. 3
    M. Chris Runken, Bridgett Goodwin, Manan Shah, Michael Eaddy, Anna D’Souza, Brian Bowers, Christopher F. Bell, Migraine-Related Healthcare Resource Use and Costs for Subjects Prescribed Fixed-Dose Combination Sumatriptan/Naproxen Sodium vs. Single-Entity Oral Triptans in a Managed Care Population in the USA, Applied Health Economics and Health Policy, 2015, 13, 1, 109

    CrossRef

  4. 4
    E. O. Gosmanova, C. P. Kovesdy, Adherence to antihypertensive medications: is prescribing the right pill enough?, Nephrology Dialysis Transplantation, 2014,

    CrossRef

  5. 5
    Chapter 3. Principles of treatment, Hypertension Research, 2014, 37, 4, 279

    CrossRef

  6. 6
    Peter Bramlage, Reinhard Ketelhut, Eva-Maria Fronk, Wolf-Peter Wolf, Rüdiger Smolnik, Claudia Zemmrich, Roland E. Schmieder, Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide, Clinical Drug Investigation, 2014, 34, 6, 403

    CrossRef

  7. 7
    Ross D. Feldman, Stanley Nattel, Increasing Appreciation for the Role of Single-Pill Combinations for the Prevention of Atherosclerotic Disease: A Pro-Polypill Polemic, Canadian Journal of Cardiology, 2014, 30, 5, 517

    CrossRef

  8. 8
    M Burnier, G Wuerzner, B Waeber, Manual of Hypertension of the European Society of Hypertension, Second Edition, 2014,

    CrossRef

  9. 9
    Dingliang Zhu, Kan Yang, Ningling Sun, Pingjin Gao, Ruonan Wang, Amie Grosso, Ying Zhang, Amlodipine/valsartan 5/160mg versus valsartan 160mg in Chinese hypertensives, International Journal of Cardiology, 2013, 167, 5, 2024

    CrossRef

  10. 10
    Manabu Akazawa, Katsushi Fukuoka, Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis, BMC Health Services Research, 2013, 13, 1, 124

    CrossRef

  11. 11
    Ross D. Feldman, Eric P. Brass, From Bad Behaviour to Bad Biology: Pitfalls and Promises in the Management of Resistant Hypertension, Canadian Journal of Cardiology, 2013, 29, 5, 549

    CrossRef

  12. You have free access to this content12
    Rainer Düsing, Patrick Brunel, InYoung Baek, Fabio Baschiera, Sustained Blood Pressure–Lowering Effect of Aliskiren Compared With Telmisartan After a Single Missed Dose, The Journal of Clinical Hypertension, 2013, 15, 1
  13. 13
    Ross D Feldman, Hypertension, 2013,

    CrossRef

  14. 14
    Joel Neutel, Ali Shojaee, Jen-Fue Maa, Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy, Advances in Therapy, 2012, 29, 6, 508

    CrossRef

  15. 15
    Serap Erdine, How do Compliance, Convenience, and Tolerability Affect Blood Pressure Goal Rates?, American Journal of Cardiovascular Drugs, 2012, 12, 5, 295

    CrossRef

  16. 16
    Charitini Stavropoulou, Perceived information needs and non-adherence: evidence from Greek patients with hypertension, Health Expectations, 2012, 15, 2
  17. You have free access to this content17
    Addison A. Taylor, Helmy Siragy, Shawna Nesbitt, Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety, The Journal of Clinical Hypertension, 2011, 13, 9
  18. 18
    Howard S Weintraub, Amy Rudolph, Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations, American Journal of Therapeutics, 2011, 18, 6, e227

    CrossRef

  19. You have free access to this content19
    A. Lowy, V. C. Munk, S. H. Ong, M. Burnier, B. Vrijens, E. P. Tousset, J. Urquhart, Effects on blood pressure and cardiovascular risk of variations in patients’ adherence to prescribed antihypertensive drugs: role of duration of drug action, International Journal of Clinical Practice, 2011, 65, 1
  20. 20
    M. Burnier, Y. Brede, A. Lowy, Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril, International Journal of Clinical Practice, 2011, 65, 2
  21. 21
    Antoni Sicras Mainar, Jordi Galera Llorca, Genís Muñoz Ortí, Ruth Navarro Artieda, Influencia del cumplimiento asociado a la incidencia de eventos cardiovasculares y los costes en combinaciones a dosis fijas en el tratamiento de la hipertensión arterial, Medicina Clínica, 2011, 136, 5, 183

    CrossRef

  22. You have free access to this content22
    Beth Sherrill, Michael Halpern, Shahnaz Khan, Jie Zhang, Sumeet Panjabi, Single-Pill vs Free-Equivalent Combination Therapies for Hypertension: A Meta-Analysis of Health Care Costs and Adherence, The Journal of Clinical Hypertension, 2011, 13, 12
  23. 23
    Atsushi Sakima, Katsuhiko Ohshiro, Seigo Nakada, Masanobu Yamazato, Kentaro Kohagura, Minori Nakamoto, Takeshi Tana, Yusuke Ohya, Switching Therapy from Variable-Dose Multiple Pill to Fixed-Dose Single-Pill Combinations of Angiotensin II Receptor Blockers and Thiazides for Hypertension, Clinical and Experimental Hypertension, 2011, 33, 5, 309

    CrossRef

  24. 24
    F. Zeng, B.V. Patel, L. Andrews, F. Frech-Tamas, A.E. Rudolph, Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens, Current Medical Research and Opinion, 2010, 26, 12, 2877

    CrossRef

  25. 25
    Joanne Chang, Weiyi Yang, Thomas Fellers, Kristijan H. Kahler, John Orloff, Jipan Xie, Magda Tsaneva, Andrew P. Yu, Eric Q. Wu, Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement, Current Medical Research and Opinion, 2010, 26, 9, 2203

    CrossRef

  26. 26
    Mohamed A. Hussein, Richard H. Chapman, Joshua S. Benner, Simon S.K. Tang, Henry A. Solomon, Amie Joyce, JoAnne M. Foody, Does a Single-Pill Antihypertensive/Lipid-Lowering Regimen Improve Adherence in US Managed Care Enrolees?, American Journal Cardiovascular Drugs, 2010, 10, 3, 193

    CrossRef

  27. 27
    Weiyi Yang, Joanne Chang, Kristijan H. Kahler, Thomas Fellers, John Orloff, Eric Q. Wu, Arielle G. Bensimon, Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives, Current Medical Research and Opinion, 2010, 26, 9, 2065

    CrossRef

  28. 28
    Brigitte Dréno, Diane Thiboutot, Harald Gollnick, Andrew Y. Finlay, Alison Layton, James J. Leyden, Eric Leutenegger, Montserrat Perez, Large-scale worldwide observational study of adherence with acne therapy, International Journal of Dermatology, 2010, 49, 4
  29. 29
    Claudio Borghi, Arrigo F. G. Cicero, Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension, Clinical Drug Investigation, 2010, 30, 12, 843

    CrossRef

  30. 30
    Michael C. Ruddy, Unmet Needs in Managing Hypertension: Potential Role of Direct Renin Inhibition, Postgraduate Medicine, 2010, 122, 3, 203

    CrossRef

  31. 31
    Francesco Vittorio Costa, Anna DʼAusilio, Cosetta Bianchi, Cristina Negrini, Stefania Lopatriello, Adherence to Antihypertensive Medications, High Blood Pressure & Cardiovascular Prevention, 2009, 16, 3, 101

    CrossRef

  32. 32
    N. Braun, H.-J. Ulmer, A. Ansari, R. Handrock, S. Klebs, Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination, Current Medical Research and Opinion, 2009, 25, 2, 421

    CrossRef

  33. 33
    Bernard Waeber, François Feihl, Luis M. Ruilope, Fixed-Dose Combinations as Initial Therapy for Hypertension, Drugs, 2009, 69, 13, 1761

    CrossRef

  34. You have free access to this content34
    M. Burnier, R. E. Brown, S. H. Ong, A. Keskinaslan, Z. M. Khan, Issues in blood pressure control and the potential role of single-pill combination therapies, International Journal of Clinical Practice, 2009, 63, 5
  35. 35
    Eduardo Pimenta, Sevikar®: combination therapy for the treatment of hypertension, Advances in Therapy, 2009, 26, 1, 1

    CrossRef

  36. 36
    J M Neutel, S S Franklin, P Lapuerta, A Bhaumik, A Ptaszynska, A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension, Journal of Human Hypertension, 2008, 22, 4, 266

    CrossRef

  37. 37
    Diana I. Brixner, Kenneth C. Jackson, II, Xiaoming Sheng, Richard E. Nelson, Abdulkadir Keskinaslan, Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations*, Current Medical Research and Opinion, 2008, 24, 9, 2597

    CrossRef

  38. 38
    Michael Dickson, Craig A Plauschinat, Compliance with Antihypertensive Therapy in the Elderly, American Journal of Cardiovascular Drugs, 2008, 8, 1, 45

    CrossRef

  39. 39
    William C. Cushman, Joel M. Neutel, Elijah Saunders, George L. Bakris, Keith C. Ferdinand, Elizabeth O. Ofili, James R. Sowers, Robert Madder, Michael A. Weber, Efficacy and Safety of Fixed Combinations of Irbesartan/Hydrochlorothiazide in Older vs Younger Patients With Hypertension Uncontrolled With Monotherapy, The American Journal of Geriatric Cardiology, 2008, 17, 1
  40. You have free access to this content40
    Yves Allemann, Belen Fraile, Michel Lambert, Michaela Barbier, Philippe Ferber, Joseph L. Izzo, Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study, The Journal of Clinical Hypertension, 2008, 10, 3
  41. 41
    Ginés Sanz, Valentin Fuster, Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population, Nature Clinical Practice Cardiovascular Medicine, 2008, 6, 2, 101

    CrossRef

  42. 42
    Jia-Rong Wu, Debra K. Moser, Terry A. Lennie, Patricia V. Burkhart, Medication Adherence in Patients Who Have Heart Failure: a Review of the Literature, Nursing Clinics of North America, 2008, 43, 1, 133

    CrossRef

  43. 43
    Fadia T. Shaya, Dongyi Du, Feride Frech-Tamas, Helen Lau, Hugh Fatodu, Howard Garber, Predictors of fixed-dose combination antihypertensive drug therapy in a Medicaid population, Journal of the American Society of Hypertension, 2008, 2, 6, 469

    CrossRef

  44. 44
    Jia-Rong Wu, Debra K. Moser, Misook L. Chung, Terry A. Lennie, Predictors of Medication Adherence Using a Multidimensional Adherence Model in Patients With Heart Failure, Journal of Cardiac Failure, 2008, 14, 7, 603

    CrossRef

  45. 45
    N. Muszbek, D. Brixner, A. Benedict, A. Keskinaslan, Z. M. Khan, The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review, International Journal of Clinical Practice, 2008, 62, 2
  46. 46
    J. A. Cramer, Á. Benedict, N. Muszbek, A. Keskinaslan, Z. M. Khan, The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review, International Journal of Clinical Practice, 2008, 62, 1
  47. You have free access to this content47
    William J. Elliott, What Factors Contribute to the Inadequate Control of Elevated Blood Pressure?, The Journal of Clinical Hypertension, 2008, 10,
  48. You have free access to this content48
    Shawna D. Nesbitt, Antihypertensive Combination Therapy: Optimizing Blood Pressure Control and Cardiovascular Risk Reduction, The Journal of Clinical Hypertension, 2007, 9,
  49. 49
    Amédé Gogovor, Alice Dragomir, Michelle Savoie, Sylvie Perreault, Comparison of Persistence Rates with Angiotensin-Converting Enzyme Inhibitors Used in Secondary and Primary Prevention of Cardiovascular Disease, Value in Health, 2007, 10, 5
  50. 50
    Sripal Bangalore, Anupama Shahane, Sanobar Parkar, Franz H. Messerli, Compliance and fixed-dose combination therapy, Current Hypertension Reports, 2007, 9, 3, 184

    CrossRef

  51. 51
    J. Schweizer, U. Hilsmann, G. Neumann, R. Handrock, S. Klebs, Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination*, Current Medical Research and Opinion, 2007, 23, 11, 2877

    CrossRef

  52. 52
    Sripal Bangalore, Gayathri Kamalakkannan, Sanobar Parkar, Franz H. Messerli, Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis, The American Journal of Medicine, 2007, 120, 8, 713

    CrossRef

  53. You have free access to this content53
    Elizabeth O. Ofili, Dispelling the Myth of “Aggressive” Antihypertensive Therapy, The Journal of Clinical Hypertension, 2006, 8,
  54. 54
    Rhian M. Touyz, Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations, Canadian Journal of Cardiology, 2006, 22, 7, 565

    CrossRef

  55. 55
    Nadia A. Khan, Finlay A. McAlister, Simon W. Rabkin, Raj Padwal, Ross D. Feldman, Norman R.C. Campbell, Lawrence A. Leiter, Richard Z. Lewanczuk, Ernesto L. Schiffrin, Michael D. Hill, Malcolm Arnold, Gordon Moe, Tavis S. Campbell, Carol Herbert, Alain Milot, James A. Stone, Ellen Burgess, B. Hemmelgarn, Charlotte Jones, Pierre Larochelle, Richard I. Ogilvie, Robyn Houlden, Robert J. Herman, Pavel Hamet, George Fodor, George Carruthers, Bruce Culleton, Jacques deChamplain, George Pylypchuk, Alexander G. Logan, Norm Gledhill, Robert Petrella, Sheldon Tobe, Rhian M. Touyz, The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – Therapy, Canadian Journal of Cardiology, 2006, 22, 7, 583

    CrossRef

  56. 56
    Eric G. Tangalos, Barbara J. Zarowitz, Combination Drug Therapy, Journal of the American Medical Directors Association, 2005, 6, 6, 406

    CrossRef

  57. 57
    Eric G. Tangalos, Barbara J. Zarowitz, Combination Drug Therapy, Journal of the American Medical Directors Association, 2005, 6, 6, 406

    CrossRef

  58. 58
    Kem P. Krueger, Bruce A. Berger, Bill Felkey, Medication adherence and persistence: A comprehensive review, Advances in Therapy, 2005, 22, 4, 313

    CrossRef

  59. 59
    Daniel R. Vanderpoel, Mohamed A. Hussein, Teresa Watson-Heidari, Andrew Perry, Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysis, Clinical Therapeutics, 2004, 26, 12, 2066

    CrossRef

  60. 60
    Addison A. Taylor, Combination drug treatment of hypertension: Have we come full circle?, Current Cardiology Reports, 2004, 6, 6, 421

    CrossRef